A Phase 3 interventional study of Setmelanotide and Placebo in Obesity and Genetic Obesity, sponsored by Rhythm Pharmaceuticals, Inc.. Completed at 66 sites in 10 countries. Open to participants aged 6 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Rhythm Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing setmelanotide in Obesity — 1 open to participants now, 2 under way, none of them phase 3. setmelanotide · Obesity.
Among the 16 studies testing setmelanotide in Obesity, this one has the largest enrollment, is one of 2 that started in 2022, is one of 6 in phase 3, and was the 13th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →1 of the 16 studies testing setmelanotide in Obesity is open now, in 1 country. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
By country, each count listing its studies:
setmelanotide: first FDA approval 2020 (IMCIVREE), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 6 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 7
First in 2012; this study’s year is marked. 2 started in 2022.
This study's enrollment of 296 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 34 across the 16 interventional studies. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 16 have an industry lead sponsor. The 2 most frequent:
Rhythm Pharmaceuticals, Inc. is the lead sponsor of 29 studies on the registry; 2 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 15 (79%) have results posted.
19 studies in Obesity by Rhythm Pharmaceuticals, Inc.: none open now, 2 under way, none of them phase 3. Of 16 finished, 10 (63%) have results posted.
Among the 19 studies in Obesity by Rhythm Pharmaceuticals, Inc., this one has the largest enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2022, is one of 6 in phase 3, and was the 15th registered.
Rhythm Pharmaceuticals, Inc.’s Obesity studies by the year they started, since 2012.
1 of the studies testing setmelanotide in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07496463Massachusetts General HospitalSetmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a) | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies testing setmelanotide in Obesity, from their registry updates:
Among Rhythm Pharmaceuticals, Inc.’s 19 in Obesity:
This tab as a report to print or save as PDF → With an account.
The protocol describes a randomized, double-blind, placebo-controlled trial with independent sub-studies of setmelanotide in participants with obesity and at least one of the specific gene variants in the Melanocortin-4 Receptor pathway:
The objectives and endpoints are identical for these sub-studies.
The criteria were revised on the registry on Nov 12, 2026. See what changed
Inclusion Criteria:
Participants must have a pre-identified:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1:1 Randomization
Drug: Setmelanotide · Drug: Placebo
1:1 Randomization
Drug: Setmelanotide · Drug: Placebo
1:1 Randomization
Drug: Setmelanotide · Drug: Placebo
1:1 Randomization
Drug: Setmelanotide · Drug: Placebo
Subcutaneous Injection
Subcutaneous Injection
Treatment Period: Percent Change From Baseline in Body Mass Index (BMI)
BMI was calculated using participant's weight and height assessments as weight in kilograms (kg)/(height in meters \[m\])\^2. Baseline was defined as the last available measurement taken prior to the start of treatment administration. An analysis of covariance (ANCOVA) model was used to calculate the least-squares mean with randomization stratification factors and baseline value as a covariate.
Time frame: Baseline, Week 52
Treatment Period: Percentage of Participants Who Achieved at Least a 5% Reduction in Baseline BMI
BMI was calculated using participant's weight and height assessments as weight in kg/(height in m)\^2. Baseline was defined as the last available measurement taken prior to the start of treatment administration.
Time frame: Baseline, Week 52
Treatment Period (Participants Aged ≥18 Years): Percent Change From Baseline in Body Weight
Data reported are for mean percent change from baseline in body weight measured in kg. Baseline was defined as the last available measurement taken prior to the start of treatment administration
Time frame: Baseline, Week 52
Treatment Period (Participants Aged ≥12 Years): Percent Change From Baseline in Weekly Average Most Hunger Score
Participants ≥12 years of age who were able to validly and reliably self-report were administered "Hunger Questions for Participants ≥12 Years of Age©." The 'most hunger' item was designed to be evaluated separately and was averaged on a weekly basis. Participants were asked 'In the last 24 hours, how hungry did you feel when you were the most hungry?' and rated their hunger on an 11-point numeric rating scale ranging from 0 to 10 (0 = not hungry at all and 10 = hungriest possible). Data reported are for mean percent change from baseline in the weekly average daily most hunger score. Baseline was defined as the last available measurement taken prior to the start of treatment administration.
Time frame: Baseline, Week 52
Treatment Period: Percentage of Participants Who Achieved at Least a 10% Reduction in Baseline BMI
BMI was calculated using participant's weight and height assessments as weight in kg/(height in m)\^2. Baseline was defined as the last available measurement taken prior to the start of treatment administration.
Time frame: Baseline, Week 52
Treatment Period (Participants <18 Years): Percent Change From Baseline in BMI Z-score
BMI z-scores were calculated according to the Centers for Disease Control and Prevention (CDC) Growth Charts and according to participant's gender and age at screening. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). A decrease in BMI Z-score (\< 0) indicates a reduction in BMI from Baseline whereas an increase in BMI-Z score (\> 0) indicated an increase in BMI from Baseline. Data reported are for mean percent change from baseline in BMI Z-score. Baseline was defined as the last available measurement taken prior to the start of treatment administration.
Time frame: Baseline, Week 52
Treatment Period (Participants <18 Years): Percent Change From Baseline in BMI 95th Percentile
The percentage change from baseline in BMI 95th percentile was calculated as (\[BMI at Week 52 / BMI 95th percentile\]) - \[BMI at baseline / BMI 95th percentile\])\*100. BMI percentile scores are measures of relative weight adjusted for child age and gender. The percent of the BMI 95th percentile score expresses the participant's BMI as a percentage of the Centers for Disease Control (CDC) 95th percentile reference population. Data reported are for mean percent change from baseline in BMI 95th percentile. Baseline was defined as the most recent measurement prior to the first administration of study drug.
Time frame: Baseline, Week 52
Treatment Period: Percent Change From Baseline in Waist Circumference
The waist circumference (in centimeters \[cm\]) was measured according to the National Heart, Lung, and Blood Institute (NHLBI) criteria. Data reported are for mean percent change from baseline in waist circumference. Baseline was defined as the last available measurement taken prior to the start of treatment administration.
Time frame: Baseline, Week 52
Treatment Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
TEAEs were defined as any untoward medical occurrence temporally associated with the use of study treatment, whether or not considered related to the study treatment that happened on or after the date of the first study treatment administration. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Baseline up to 60 weeks
Treatment Period (Participants ≥18 Years): Percent Change From Baseline in Physical Functioning Score on the Impact of Weight on Quality of Life (IWQOL)-Lite
The IWQOL-Lite is a validated 31-item self-reported measure of obesity-specific quality of life questionnaire. The physical function domain comprised 11 items which had 5 response items: Always True=5, Usually True=4, Sometimes True=3, Rarely True=2, Never True=1. The score of each item was summed to calculate the raw score. The raw score range of the physical function domain was 11-55 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) \*100. Data reported are for mean percent change from baseline in physical functioning score on the IWQOL-Lite. Baseline was defined as the last available measurement taken prior to the start of treatment administration.
Time frame: Baseline, Week 52
Treatment Period (Participants 11 to <18 Years): Percent Change From Baseline in Physical Comfort Score on the IWQOL-Kids-Parent-Proxy
The IWQOL-Kids-Parent-Proxy is a psychometrically validated 27-item self-reported measure of obesity-specific quality of life questionnaire. The physical comfort domain comprised 6 items which used a 5-point Likert scale: Always True=1, Usually True=2, Sometimes True=3, Rarely True=4, Never True=5. The items were summed to calculate the raw score. The raw score range of the physical function domain was 6-30 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) \*100. Data reported are for mean percent change from baseline in Physical Comfort Score on the IWQOL-Kids-Parent-Proxy. Baseline was defined as the last available measurement taken prior to the start of treatment administration.
Time frame: Baseline, Week 52
Treatment Period (Participants ≥18 Years): Percent Change From Baseline in Impact on Quality of Life Total Score on the IWQOL-Lite
The IWQOL-Lite is a validated 31-item self-reported measure of obesity-specific quality of life questionnaire which comprised of 5 domains (physical function, self-esteem, sexual life, distress and work) and had 5 response items: Always True=5, Usually True=4, Sometimes True=3, Rarely True=2, Never True=1. The items were summed to calculate the raw total score. The raw total score range was 31-155 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) \*100. Data reported are for mean percent change from baseline in Impact on Quality of Life Total Score on the IWQOL-Lite. Baseline was defined as the last available measurement taken prior to the start of treatment administration.
Time frame: Baseline, Week 52
Treatment Period (Participants 11 to <18 Years): Percent Change From Baseline in Impact on Quality of Life Total Score on the IWQOL-Kids-Parent-Proxy
The IWQOL-Kids-Parent-Proxy is a psychometrically validated 27-item self-reported measure of obesity-specific quality of life questionnaire and comprised of 4 domains (physical comfort, body esteem, social life, family relations) and used a 5-point Likert scale: Always True=1, Usually True=2, Sometimes True=3, Rarely True=4, Never True=5. The items were summed to calculate the raw total score. The raw total score range was 27 to 135 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) \*100. Data reported are for mean percent change from baseline in Impact on Quality of Life Total Score on the IWQOL-Kids-Parent-Proxy. Baseline was defined as the last available measurement taken prior to the start of treatment administration.
Time frame: Baseline, Week 52
Treatment Period: Percent Change From Baseline in Body Weight in Setmelanotide Initial Responders Versus Placebo
Initial responders were defined as setmelanotide treated participants with ≥5% body weight loss (≥18 years of age) or a decrease in BMI by ≥3% (\<18 years of age) at the time of consecutive 12 weeks with the increased 3.0 mg/day or with final increased dose level. Data reported are for mean percent change from baseline in body weight measured in kg. Baseline was defined as the last available measurement taken prior to the start of treatment administration.
Time frame: Baseline, Week 52
| Milestone | Sub-study 035a: Setmelanotide | Sub-study 035a: Placebo | Sub-study 035b: Setmelanotide | Sub-study 035b: Placebo | Sub-study 035c: Setmelanotide | Sub-study 035c: Placebo | Sub-study 035d: Setmelanotide | Sub-study 035d: Placebo |
|---|---|---|---|---|---|---|---|---|
| Started | 39 | 40 | 11 | 12 | 36 | 37 | 61 | 60 |
| Received at least one dose of study drug | 39 | 39 | 11 | 12 | 36 | 37 | 61 | 60 |
| Completed | 21 | 24 | 8 | 6 | 15 | 15 | 32 | 31 |
| Not completed | 18 | 16 | 3 | 6 | 21 | 22 | 29 | 29 |
| Withdrew: Adverse event | 8 | 3 | 1 | 1 | 9 | 1 | 12 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 0 | 2 | 1 | 1 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 | 4 | 0 | 0 |
| Withdrew: Protocol violation | 2 | 4 | 0 | 1 | 1 | 0 | 0 | 3 |
| Withdrew: Withdrawal of consent | 2 | 2 | 1 | 2 | 1 | 5 | 7 | 6 |
| Withdrew: Participant decision | 6 | 6 | 1 | 2 | 9 | 10 | 9 | 17 |
| Milestone | Sub-study 035a: Setmelanotide | Sub-study 035a: Placebo | Sub-study 035b: Setmelanotide | Sub-study 035b: Placebo | Sub-study 035c: Setmelanotide | Sub-study 035c: Placebo | Sub-study 035d: Setmelanotide | Sub-study 035d: Placebo |
|---|---|---|---|---|---|---|---|---|
| Started | 17 | 25 | 7 | 8 | 14 | 14 | 27 | 30 |
| Completed | 6 | 6 | 6 | 6 | 5 | 3 | 9 | 13 |
| Not completed | 11 | 19 | 1 | 2 | 9 | 11 | 18 | 17 |
| Withdrew: Adverse event | 1 | 2 | 0 | 1 | 0 | 1 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Study ended due to sponsor decision | 5 | 12 | 0 | 0 | 3 | 7 | 7 | 9 |
| Withdrew: Protocol violation | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal of consent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Participant decision | 3 | 2 | 0 | 1 | 5 | 3 | 9 | 3 |
| Withdrew: End-of-study assessments not completed | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BMI was calculated using participant's weight and height assessments as weight in kilograms (kg)/(height in meters \[m\])\^2. Baseline was defined as the last available measurement taken prior to the start of treatment administration. An analysis of covariance (ANCOVA) model was used to calculate the least-squares mean with randomization stratification factors and baseline value as a covariate.
| percent change | Treatment Period (Sub-study 035a): Setmelanotide | Treatment Period (Sub-study 035a): Placebo | Treatment Period (Sub-study 035b): Setmelanotide | Treatment Period (Sub-study 035b): Placebo | Treatment Period (Sub-study 035c): Setmelanotide | Treatment Period (Sub-study 035c): Placebo | Treatment Period (Sub-study 035d): Setmelanotide | Treatment Period (Sub-study 035d): Placebo |
|---|---|---|---|---|---|---|---|---|
| Treatment Period: Percent Change From Baseline in Body Mass Index (BMI) | -3.443 ± 2.9914 | 0.850 ± 2.4443 | -7.627 ± 29.7282 | -4.056 ± 27.7687 | -0.908 ± 3.5361 | 3.139 ± 3.8652 | -0.644 ± 1.8441 | 1.089 ± 2.2102 |
BMI was calculated using participant's weight and height assessments as weight in kg/(height in m)\^2. Baseline was defined as the last available measurement taken prior to the start of treatment administration.
| percentage of participants | Treatment Period (Sub-study 035a): Setmelanotide | Treatment Period (Sub-study 035a): Placebo | Treatment Period (Sub-study 035b): Setmelanotide | Treatment Period (Sub-study 035b): Placebo | Treatment Period (Sub-study 035c): Setmelanotide | Treatment Period (Sub-study 035c): Placebo | Treatment Period (Sub-study 035d): Setmelanotide | Treatment Period (Sub-study 035d): Placebo |
|---|---|---|---|---|---|---|---|---|
| Treatment Period: Percentage of Participants Who Achieved at Least a 5% Reduction in Baseline BMI | 34.21 (21.212 to 50.108) | 10.00 (3.958 to 23.052) | 45.45 (21.271 to 71.991) | 16.67 (4.697 to 44.803) | 25.00 (13.750 to 41.070) | 5.41 (1.495 to 17.705) | 16.39 (9.156 to 27.613) | 11.67 (5.768 to 22.179) |
Data reported are for mean percent change from baseline in body weight measured in kg. Baseline was defined as the last available measurement taken prior to the start of treatment administration
| percent change | Treatment Period (Sub-study 035a): Setmelanotide | Treatment Period (Sub-study 035a): Placebo | Treatment Period (Sub-study 035b): Setmelanotide | Treatment Period (Sub-study 035b): Placebo | Treatment Period (Sub-study 035c): Setmelanotide | Treatment Period (Sub-study 035c): Placebo | Treatment Period (Sub-study 035d): Setmelanotide | Treatment Period (Sub-study 035d): Placebo |
|---|---|---|---|---|---|---|---|---|
| Treatment Period (Participants Aged ≥18 Years): Percent Change From Baseline in Body Weight | -7.12 ± 2.137 | -0.05 ± 2.042 | -4.53 ± 1.095 | -6.47 ± 2.497 | -7.88 ± 3.007 | -1.19 ± 2.693 | -7.52 ± 2.858 | -2.46 ± 1.968 |
Participants ≥12 years of age who were able to validly and reliably self-report were administered "Hunger Questions for Participants ≥12 Years of Age©." The 'most hunger' item was designed to be evaluated separately and was averaged on a weekly basis. Participants were asked 'In the last 24 hours, how hungry did you feel when you were the most hungry?' and rated their hunger on an 11-point numeric rating scale ranging from 0 to 10 (0 = not hungry at all and 10 = hungriest possible). Data reported are for mean percent change from baseline in the weekly average daily most hunger score. Baseline was defined as the last available measurement taken prior to the start of treatment administration.
| percent change | Treatment Period (Sub-study 035a): Setmelanotide | Treatment Period (Sub-study 035a): Placebo | Treatment Period (Sub-study 035b): Setmelanotide | Treatment Period (Sub-study 035b): Placebo | Treatment Period (Sub-study 035c): Setmelanotide | Treatment Period (Sub-study 035c): Placebo | Treatment Period (Sub-study 035d): Setmelanotide | Treatment Period (Sub-study 035d): Placebo |
|---|---|---|---|---|---|---|---|---|
| Treatment Period (Participants Aged ≥12 Years): Percent Change From Baseline in Weekly Average Most Hunger Score | -32.822 ± 9.3805 | -22.854 ± 10.8763 | -16.934 ± 8.1462 | -24.607 ± 27.6919 | -45.802 ± 7.4226 | -15.927 ± 9.1348 | -45.331 ± 6.7007 | 8.075 ± 28.9737 |
BMI was calculated using participant's weight and height assessments as weight in kg/(height in m)\^2. Baseline was defined as the last available measurement taken prior to the start of treatment administration.
| percentage of participants | Treatment Period (Sub-study 035a): Setmelanotide | Treatment Period (Sub-study 035a): Placebo | Treatment Period (Sub-study 035b): Setmelanotide | Treatment Period (Sub-study 035b): Placebo | Treatment Period (Sub-study 035c): Setmelanotide | Treatment Period (Sub-study 035c): Placebo | Treatment Period (Sub-study 035d): Setmelanotide | Treatment Period (Sub-study 035d): Placebo |
|---|---|---|---|---|---|---|---|---|
| Treatment Period: Percentage of Participants Who Achieved at Least a 10% Reduction in Baseline BMI | 21.05 (11.075 to 36.346) | 5.00 (1.382 to 16.504) | 9.09 (1.623 to 37.736) | 16.67 (4.697 to 44.803) | 16.67 (7.870 to 31.891) | 2.70 (0.479 to 13.824) | 6.56 (2.579 to 15.683) | 6.67 (2.623 to 15.925) |
BMI z-scores were calculated according to the Centers for Disease Control and Prevention (CDC) Growth Charts and according to participant's gender and age at screening. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). A decrease in BMI Z-score (\< 0) indicates a reduction in BMI from Baseline whereas an increase in BMI-Z score (\> 0) indicated an increase in BMI from Baseline. Data reported are for mean percent change from baseline in BMI Z-score. Baseline was defined as the last available measurement taken prior to the start of treatment administration.
| percent change | Treatment Period (Sub-study 035a): Setmelanotide | Treatment Period (Sub-study 035a): Placebo | Treatment Period (Sub-study 035b): Setmelanotide | Treatment Period (Sub-study 035b): Placebo | Treatment Period (Sub-study 035c): Setmelanotide | Treatment Period (Sub-study 035c): Placebo | Treatment Period (Sub-study 035d): Setmelanotide | Treatment Period (Sub-study 035d): Placebo |
|---|---|---|---|---|---|---|---|---|
| Treatment Period (Participants <18 Years): Percent Change From Baseline in BMI Z-score | -18.133 ± 13.5307 | -0.622 ± 14.1909 | -30.599 ± 27.6093 | -17.820 ± 4.3825 | -14.882 ± 13.4953 | 1.607 ± 7.7502 | -5.229 ± 10.8090 | -3.701 ± 8.0116 |
The percentage change from baseline in BMI 95th percentile was calculated as (\[BMI at Week 52 / BMI 95th percentile\]) - \[BMI at baseline / BMI 95th percentile\])\*100. BMI percentile scores are measures of relative weight adjusted for child age and gender. The percent of the BMI 95th percentile score expresses the participant's BMI as a percentage of the Centers for Disease Control (CDC) 95th percentile reference population. Data reported are for mean percent change from baseline in BMI 95th percentile. Baseline was defined as the most recent measurement prior to the first administration of study drug.
| percent change | Treatment Period (Sub-study 035a): Setmelanotide | Treatment Period (Sub-study 035a): Placebo | Treatment Period (Sub-study 035b): Setmelanotide | Treatment Period (Sub-study 035b): Placebo | Treatment Period (Sub-study 035c): Setmelanotide | Treatment Period (Sub-study 035c): Placebo | Treatment Period (Sub-study 035d): Setmelanotide | Treatment Period (Sub-study 035d): Placebo |
|---|---|---|---|---|---|---|---|---|
| Treatment Period (Participants <18 Years): Percent Change From Baseline in BMI 95th Percentile | -11.254 ± 8.5814 | -0.207 ± 8.4137 | -11.418 ± 5.3544 | -9.547 ± 3.1399 | -8.815 ± 8.5459 | 1.438 ± 4.2150 | -2.482 ± 6.4485 | -1.394 ± 4.7956 |
The waist circumference (in centimeters \[cm\]) was measured according to the National Heart, Lung, and Blood Institute (NHLBI) criteria. Data reported are for mean percent change from baseline in waist circumference. Baseline was defined as the last available measurement taken prior to the start of treatment administration.
| percent change | Treatment Period (Sub-study 035a): Setmelanotide | Treatment Period (Sub-study 035a): Placebo | Treatment Period (Sub-study 035b): Setmelanotide | Treatment Period (Sub-study 035b): Placebo | Treatment Period (Sub-study 035c): Setmelanotide | Treatment Period (Sub-study 035c): Placebo | Treatment Period (Sub-study 035d): Setmelanotide | Treatment Period (Sub-study 035d): Placebo |
|---|---|---|---|---|---|---|---|---|
| Treatment Period: Percent Change From Baseline in Waist Circumference | -5.839 ± 7.7945 | 2.156 ± 9.6472 | -2.130 ± 5.0095 | -2.796 ± 7.3768 | -8.241 ± 7.4749 | 1.332 ± 7.6061 | -2.918 ± 7.4923 | -1.521 ± 12.4120 |
TEAEs were defined as any untoward medical occurrence temporally associated with the use of study treatment, whether or not considered related to the study treatment that happened on or after the date of the first study treatment administration. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | Treatment Period (Sub-study 035a): Setmelanotide | Treatment Period (Sub-study 035a): Placebo | Treatment Period (Sub-study 035b): Setmelanotide | Treatment Period (Sub-study 035b): Placebo | Treatment Period (Sub-study 035c): Setmelanotide | Treatment Period (Sub-study 035c): Placebo | Treatment Period (Sub-study 035d): Setmelanotide | Treatment Period (Sub-study 035d): Placebo |
|---|---|---|---|---|---|---|---|---|
| Treatment Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 38 | 35 | 10 | 11 | 36 | 36 | 61 | 57 |
The IWQOL-Lite is a validated 31-item self-reported measure of obesity-specific quality of life questionnaire. The physical function domain comprised 11 items which had 5 response items: Always True=5, Usually True=4, Sometimes True=3, Rarely True=2, Never True=1. The score of each item was summed to calculate the raw score. The raw score range of the physical function domain was 11-55 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) \*100. Data reported are for mean percent change from baseline in physical functioning score on the IWQOL-Lite. Baseline was defined as the last available measurement taken prior to the start of treatment administration.
| percent change | Treatment Period (Sub-study 035a): Setmelanotide | Treatment Period (Sub-study 035a): Placebo | Treatment Period (Sub-study 035b): Setmelanotide | Treatment Period (Sub-study 035b): Placebo | Treatment Period (Sub-study 035c): Setmelanotide | Treatment Period (Sub-study 035c): Placebo | Treatment Period (Sub-study 035d): Setmelanotide | Treatment Period (Sub-study 035d): Placebo |
|---|---|---|---|---|---|---|---|---|
| Treatment Period (Participants ≥18 Years): Percent Change From Baseline in Physical Functioning Score on the Impact of Weight on Quality of Life (IWQOL)-Lite | 16.59 ± 42.171 | 38.60 ± 52.602 | 0.16 ± 21.597 | 31.82 | 25.61 ± 58.299 | 5.98 ± 21.154 | 70.29 ± 128.251 | 19.01 ± 56.276 |
The IWQOL-Kids-Parent-Proxy is a psychometrically validated 27-item self-reported measure of obesity-specific quality of life questionnaire. The physical comfort domain comprised 6 items which used a 5-point Likert scale: Always True=1, Usually True=2, Sometimes True=3, Rarely True=4, Never True=5. The items were summed to calculate the raw score. The raw score range of the physical function domain was 6-30 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) \*100. Data reported are for mean percent change from baseline in Physical Comfort Score on the IWQOL-Kids-Parent-Proxy. Baseline was defined as the last available measurement taken prior to the start of treatment administration.
| percent change | Treatment Period (Sub-study 035a): Setmelanotide | Treatment Period (Sub-study 035a): Placebo | Treatment Period (Sub-study 035b): Setmelanotide | Treatment Period (Sub-study 035b): Placebo | Treatment Period (Sub-study 035c): Setmelanotide | Treatment Period (Sub-study 035c): Placebo | Treatment Period (Sub-study 035d): Setmelanotide | Treatment Period (Sub-study 035d): Placebo |
|---|---|---|---|---|---|---|---|---|
| Treatment Period (Participants 11 to <18 Years): Percent Change From Baseline in Physical Comfort Score on the IWQOL-Kids-Parent-Proxy | 21.04 ± 36.687 | 44.38 ± 65.426 | 63.19 ± 8.547 | 41.67 | 5.00 ± 34.631 | 45.00 ± 77.782 | 63.84 ± 98.629 | 55.76 ± 64.444 |
The IWQOL-Lite is a validated 31-item self-reported measure of obesity-specific quality of life questionnaire which comprised of 5 domains (physical function, self-esteem, sexual life, distress and work) and had 5 response items: Always True=5, Usually True=4, Sometimes True=3, Rarely True=2, Never True=1. The items were summed to calculate the raw total score. The raw total score range was 31-155 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) \*100. Data reported are for mean percent change from baseline in Impact on Quality of Life Total Score on the IWQOL-Lite. Baseline was defined as the last available measurement taken prior to the start of treatment administration.
| percent change | Treatment Period (Sub-study 035a): Setmelanotide | Treatment Period (Sub-study 035a): Placebo | Treatment Period (Sub-study 035b): Setmelanotide | Treatment Period (Sub-study 035b): Placebo | Treatment Period (Sub-study 035c): Setmelanotide | Treatment Period (Sub-study 035c): Placebo | Treatment Period (Sub-study 035d): Setmelanotide | Treatment Period (Sub-study 035d): Placebo |
|---|---|---|---|---|---|---|---|---|
| Treatment Period (Participants ≥18 Years): Percent Change From Baseline in Impact on Quality of Life Total Score on the IWQOL-Lite | 20.115 ± 29.1744 | 37.596 ± 58.5983 | 8.369 ± 29.3163 | 11.236 | 35.361 ± 71.6930 | 21.217 ± 11.1095 | 42.751 ± 79.7561 | 40.105 ± 73.6256 |
The IWQOL-Kids-Parent-Proxy is a psychometrically validated 27-item self-reported measure of obesity-specific quality of life questionnaire and comprised of 4 domains (physical comfort, body esteem, social life, family relations) and used a 5-point Likert scale: Always True=1, Usually True=2, Sometimes True=3, Rarely True=4, Never True=5. The items were summed to calculate the raw total score. The raw total score range was 27 to 135 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) \*100. Data reported are for mean percent change from baseline in Impact on Quality of Life Total Score on the IWQOL-Kids-Parent-Proxy. Baseline was defined as the last available measurement taken prior to the start of treatment administration.
| percent change | Treatment Period (Sub-study 035a): Setmelanotide | Treatment Period (Sub-study 035a): Placebo | Treatment Period (Sub-study 035b): Setmelanotide | Treatment Period (Sub-study 035b): Placebo | Treatment Period (Sub-study 035c): Setmelanotide | Treatment Period (Sub-study 035c): Placebo | Treatment Period (Sub-study 035d): Setmelanotide | Treatment Period (Sub-study 035d): Placebo |
|---|---|---|---|---|---|---|---|---|
| Treatment Period (Participants 11 to <18 Years): Percent Change From Baseline in Impact on Quality of Life Total Score on the IWQOL-Kids-Parent-Proxy | 12.295 ± 18.1648 | 30.985 ± 68.1076 | 23.814 ± 8.5369 | 7.042 | 0.091 ± 8.7346 | -2.617 ± 7.9226 | 9.313 ± 30.6953 | 36.630 ± 18.3963 |
Initial responders were defined as setmelanotide treated participants with ≥5% body weight loss (≥18 years of age) or a decrease in BMI by ≥3% (\<18 years of age) at the time of consecutive 12 weeks with the increased 3.0 mg/day or with final increased dose level. Data reported are for mean percent change from baseline in body weight measured in kg. Baseline was defined as the last available measurement taken prior to the start of treatment administration.
| percent change | Treatment Period (Sub-study 035a): Setmelanotide | Treatment Period (Sub-study 035a): Placebo | Treatment Period (Sub-study 035b): Setmelanotide | Treatment Period (Sub-study 035b): Placebo | Treatment Period (Sub-study 035c): Setmelanotide | Treatment Period (Sub-study 035c): Placebo | Treatment Period (Sub-study 035d): Setmelanotide | Treatment Period (Sub-study 035d): Placebo |
|---|---|---|---|---|---|---|---|---|
| Treatment Period: Percent Change From Baseline in Body Weight in Setmelanotide Initial Responders Versus Placebo | -7.84 ± 8.123 | 5.09 ± 10.729 | -5.89 ± 2.743 | -3.72 ± 6.801 | -11.23 ± 9.665 | 4.52 ± 9.951 | -5.53 ± 13.041 | 1.78 ± 9.795 |
Collected over Treatment Period: Up to Week 60. Bridging Period: Up to a maximum of 132 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Period (Sub-study 035a): Setmelanotide | 0/39 (0%) | 3/39 (7.7%) | 38/39 (97.4%) |
| Treatment Period (Sub-study 035a): Placebo | 0/40 (0%) | 2/39 (5.1%) | 35/39 (89.7%) |
| Treatment Period (Sub-study 035b): Setmelanotide | 0/11 (0%) | 0/11 (0%) | 10/11 (90.9%) |
| Treatment Period (Sub-study 035b): Placebo | 0/12 (0%) | 0/12 (0%) | 11/12 (91.7%) |
| Treatment Period (Sub-study 035c): Setmelanotide | 0/36 (0%) | 1/36 (2.8%) | 36/36 (100%) |
| Treatment Period (Sub-study 035c): Placebo | 0/37 (0%) | 2/37 (5.4%) | 36/37 (97.3%) |
| Treatment Period (Sub-study 035d): Setmelanotide | 0/61 (0%) | 3/61 (4.9%) | 61/61 (100%) |
| Treatment Period (Sub-study 035d): Placebo | 0/60 (0%) | 5/60 (8.3%) | 57/60 (95%) |
| Bridging Period (Sub-study 035a): Setmelanotide to Setmelanotide | 0/17 (0%) | 2/17 (11.8%) | 12/17 (70.6%) |
| Bridging Period (Sub-study 035a): Placebo to Setmelanotide | 0/25 (0%) | 2/25 (8%) | 23/25 (92%) |
| Bridging Period (Sub-study 035b): Setmelanotide to Setmelanotide | 0/7 (0%) | 0/7 (0%) | 4/7 (57.1%) |
| Bridging Period (Sub-study 035b): Placebo to Setmelanotide | 0/8 (0%) | 0/8 (0%) | 8/8 (100%) |
| Bridging Period (Sub-study 035c): Setmelanotide to Setmelanotide | 0/14 (0%) | 1/14 (7.1%) | 13/14 (92.9%) |
| Bridging Period (Sub-study 035c): Placebo to Setmelanotide | 0/14 (0%) | 0/14 (0%) | 14/14 (100%) |
| Bridging Period (Sub-study 035d): Setmelanotide to Setmelanotide | 0/27 (0%) | 1/27 (3.7%) | 19/27 (70.4%) |
| Bridging Period (Sub-study 035d): Placebo to Setmelanotide | 0/30 (0%) | 2/30 (6.7%) | 27/30 (90%) |
| Event | Treatment Period (Sub-study 035a): Setmelanotide | Treatment Period (Sub-study 035a): Placebo | Treatment Period (Sub-study 035b): Setmelanotide | Treatment Period (Sub-study 035b): Placebo | Treatment Period (Sub-study 035c): Setmelanotide | Treatment Period (Sub-study 035c): Placebo | Treatment Period (Sub-study 035d): Setmelanotide | Treatment Period (Sub-study 035d): Placebo | Bridging Period (Sub-study 035a): Setmelanotide to Setmelanotide | Bridging Period (Sub-study 035a): Placebo to Setmelanotide | Bridging Period (Sub-study 035b): Setmelanotide to Setmelanotide | Bridging Period (Sub-study 035b): Placebo to Setmelanotide | Bridging Period (Sub-study 035c): Setmelanotide to Setmelanotide | Bridging Period (Sub-study 035c): Placebo to Setmelanotide | Bridging Period (Sub-study 035d): Setmelanotide to Setmelanotide | Bridging Period (Sub-study 035d): Placebo to Setmelanotide |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 0/39 | 0/39 | 0/11 | 0/12 | 0/36 | 0/37 | 0/61 | 0/60 | 0/17 | 0/25 | 0/7 | 0/8 | 1/14 | 0/14 | 0/27 | 0/30 |
| Liver function test increasedInvestigations | 0/39 | 0/39 | 0/11 | 0/12 | 0/36 | 0/37 | 0/61 | 0/60 | 0/17 | 0/25 | 0/7 | 0/8 | 1/14 | 0/14 | 0/27 | 0/30 |
| SepsisInfections and infestations | 0/39 | 0/39 | 0/11 | 0/12 | 0/36 | 0/37 | 0/61 | 0/60 | 1/17 | 0/25 | 0/7 | 0/8 | 0/14 | 0/14 | 0/27 | 0/30 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/39 | 0/39 | 0/11 | 0/12 | 0/36 | 0/37 | 0/61 | 0/60 | 1/17 | 0/25 | 0/7 | 0/8 | 0/14 | 0/14 | 0/27 | 0/30 |
| TeratomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/39 | 0/39 | 0/11 | 0/12 | 0/36 | 0/37 | 0/61 | 0/60 | 0/17 | 1/25 | 0/7 | 0/8 | 0/14 | 0/14 | 0/27 | 0/30 |
| DepressionPsychiatric disorders | 0/39 | 0/39 | 0/11 | 0/12 | 0/36 | 0/37 | 0/61 | 0/60 | 0/17 | 1/25 | 0/7 | 0/8 | 0/14 | 0/14 | 0/27 | 0/30 |
| Angina unstableCardiac disorders | 0/39 | 0/39 | 0/11 | 0/12 | 0/36 | 0/37 | 0/61 | 1/60 | 0/17 | 0/25 | 0/7 | 0/8 | 0/14 | 0/14 | 1/27 | 0/30 |
| Kidney infectionInfections and infestations | 0/39 | 0/39 | 0/11 | 0/12 | 0/36 | 0/37 | 0/61 | 0/60 | 0/17 | 0/25 | 0/7 | 0/8 | 0/14 | 0/14 | 0/27 | 1/30 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/39 | 0/39 | 0/11 | 0/12 | 0/36 | 0/37 | 0/61 | 0/60 | 0/17 | 0/25 | 0/7 | 0/8 | 0/14 | 0/14 | 0/27 | 1/30 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/39 | 0/39 | 0/11 | 0/12 | 0/36 | 0/37 | 0/61 | 0/60 | 0/17 | 0/25 | 0/7 | 0/8 | 0/14 | 0/14 | 0/27 | 1/30 |
| Event | Treatment Period (Sub-study 035a): Setmelanotide | Treatment Period (Sub-study 035a): Placebo | Treatment Period (Sub-study 035b): Setmelanotide | Treatment Period (Sub-study 035b): Placebo | Treatment Period (Sub-study 035c): Setmelanotide | Treatment Period (Sub-study 035c): Placebo | Treatment Period (Sub-study 035d): Setmelanotide | Treatment Period (Sub-study 035d): Placebo | Bridging Period (Sub-study 035a): Setmelanotide to Setmelanotide | Bridging Period (Sub-study 035a): Placebo to Setmelanotide | Bridging Period (Sub-study 035b): Setmelanotide to Setmelanotide | Bridging Period (Sub-study 035b): Placebo to Setmelanotide | Bridging Period (Sub-study 035c): Setmelanotide to Setmelanotide | Bridging Period (Sub-study 035c): Placebo to Setmelanotide | Bridging Period (Sub-study 035d): Setmelanotide to Setmelanotide | Bridging Period (Sub-study 035d): Placebo to Setmelanotide |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Skin hyperpigmentationSkin and subcutaneous tissue disorders | 32/39 | 7/39 | 10/11 | 3/12 | 30/36 | 10/37 | 52/61 | 24/60 | 0/17 | 19/25 | 0/7 | 8/8 | 2/14 | 12/14 | 2/27 | 21/30 |
| NauseaGastrointestinal disorders | 17/39 | 12/39 | 1/11 | 2/12 | 17/36 | 6/37 | 26/61 | 16/60 | 1/17 | 8/25 | 0/7 | 2/8 | 2/14 | 8/14 | 3/27 | 6/30 |
| Injection site erythemaGeneral disorders | 14/39 | 17/39 | 6/11 | 4/12 | 13/36 | 20/37 | 25/61 | 30/60 | 1/17 | 2/25 | 0/7 | 1/8 | 3/14 | 3/14 | 2/27 | 4/30 |
| Melanocytic naevusNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 20/39 | 5/39 | 6/11 | 1/12 | 15/36 | 2/37 | 25/61 | 6/60 | 1/17 | 8/25 | 1/7 | 1/8 | 2/14 | 7/14 | 1/27 | 6/30 |
| Injection site pruritusGeneral disorders | 9/39 | 8/39 | 3/11 | 1/12 | 16/36 | 16/37 | 21/61 | 13/60 | 0/17 | 0/25 | 1/7 | 1/8 | 1/14 | 2/14 | 2/27 | 3/30 |
| Erection increasedReproductive system and breast disorders | 5/18 | 1/17 | 2/5 | 1/5 | 0/11 | 1/13 | 6/24 | 1/27 | 0/6 | 1/12 | 0/3 | 1/4 | 0/2 | 1/7 | 1/11 | 2/13 |
| Injection site painGeneral disorders | 13/39 | 14/39 | 4/11 | 3/12 | 14/36 | 14/37 | 17/61 | 19/60 | 0/17 | 0/25 | 1/7 | 0/8 | 2/14 | 2/14 | 0/27 | 1/30 |
| Injection site indurationGeneral disorders | 13/39 | 12/39 | 3/11 | 2/12 | 8/36 | 13/37 | 20/61 | 12/60 | 0/17 | 1/25 | 1/7 | 0/8 | 1/14 | 2/14 | 1/27 | 3/30 |
| HeadacheNervous system disorders | 9/39 | 9/39 | 3/11 | 3/12 | 6/36 | 7/37 | 20/61 | 6/60 | 0/17 | 3/25 | 1/7 | 2/8 | 1/14 | 2/14 | 3/27 | 7/30 |
| VomitingGastrointestinal disorders | 12/39 | 7/39 | 1/11 | 1/12 | 11/36 | 3/37 | 13/61 | 8/60 | 0/17 | 8/25 | 1/7 | 1/8 | 0/14 | 1/14 | 4/27 | 3/30 |
The Intent-to-treat (ITT) set included all randomized participants regardless of treatment adherence and availability of baseline data.
| Age, Customized(Participants) | Sub-study 035a: Setmelanotide | Sub-study 035a: Placebo | Sub-study 035b: Setmelanotide | Sub-study 035b: Placebo | Sub-study 035c: Setmelanotide | Sub-study 035c: Placebo | Sub-study 035d: Setmelanotide | Sub-study 035d: Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|
| Aged 6 to <12 years | 10 | 10 | 3 | 4 | 6 | 5 | 14 | 15 | 67 |
| Aged 12 to <18 years | 11 | 11 | 3 | 2 | 11 | 12 | 14 | 14 | 78 |
| Aged 18 to ≤65 years | 18 | 19 | 5 | 6 | 19 | 20 | 33 | 31 | 151 |
| Sex: Female, Male(Participants) | Sub-study 035a: Setmelanotide | Sub-study 035a: Placebo | Sub-study 035b: Setmelanotide | Sub-study 035b: Placebo | Sub-study 035c: Setmelanotide | Sub-study 035c: Placebo | Sub-study 035d: Setmelanotide | Sub-study 035d: Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 21 | 23 | 6 | 7 | 25 | 24 | 37 | 33 | 176 |
| Male | 18 | 17 | 5 | 5 | 11 | 13 | 24 | 27 | 120 |
| Ethnicity (NIH/OMB)(Participants) | Sub-study 035a: Setmelanotide | Sub-study 035a: Placebo | Sub-study 035b: Setmelanotide | Sub-study 035b: Placebo | Sub-study 035c: Setmelanotide | Sub-study 035c: Placebo | Sub-study 035d: Setmelanotide | Sub-study 035d: Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 5 | 3 | 1 | 2 | 11 | 11 | 15 | 13 | 61 |
| Not Hispanic or Latino | 32 | 37 | 8 | 9 | 25 | 26 | 42 | 45 | 224 |
| Unknown or Not Reported | 2 | 0 | 2 | 1 | 0 | 0 | 4 | 2 | 11 |
| Race/Ethnicity, Customized(Participants) | Sub-study 035a: Setmelanotide | Sub-study 035a: Placebo | Sub-study 035b: Setmelanotide | Sub-study 035b: Placebo | Sub-study 035c: Setmelanotide | Sub-study 035c: Placebo | Sub-study 035d: Setmelanotide | Sub-study 035d: Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|
| Race — Black or African American | 1 | 2 | 1 | 1 | 2 | 5 | 8 | 7 | 27 |
| Race — American Indian or Alaska Native | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 3 |
| Race — Asian | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 2 |
| Race — White | 36 | 35 | 9 | 9 | 29 | 27 | 47 | 45 | 237 |
| Race — Other | 0 | 3 | 0 | 0 | 3 | 3 | 0 | 5 | 14 |
| Race — Not Reported | 2 | 0 | 1 | 1 | 0 | 0 | 4 | 2 | 10 |
| Race — Unknown | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2022 to primary completion in Dec 2025, 43 months.
Results were first posted in Nov 2026, 10 months after primary completion.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 43 months is above that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
Start moved once since we started tracking on Sep 25, 2026: Dec 2021 → Apr 2022, on Nov 12, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Setmelanotide
Rhythm Pharmaceuticals, Inc. →